Kenneth Galbraith, Zymeworks CEO
#ASCO22: As it dodges a takeover bid, Zymeworks wants what Daiichi Sankyo got: a massive Big Pharma partner
CHICAGO — The Daiichi Sankyo story made waves Sunday at the annual ASCO meeting in Chicago, as Enhertu potentially disrupted the breast cancer landscape by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.